The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
I think we should see the RNS as a positive. Yes we may have made a small loss on the partial sale of Vemo, but then the adoption of ISAs in the US was always going to be a slow burner. How many universities in the US have actually adopted Vemo's solution? Not that many to date. On the other hand if they reinvest the money into another medical cannabis company the returns could be substantially higher over the short term. Medical cannabis is a very hot industry at present and several private medical cannabis companies are considering IPOs soon. Emmac alone could net us a 5 bag return when it IPOs, and so others could also. I imagine the board have weighed it up carefully in taking this decision.
...better watch out, better beware, Albert says E = mc2, Einstein Vogogo....
Yes, great article. It really illustrates FFWD's approach of looking for the very best companies in some of the fastest growing industries, led by the most talented in those industries. Emmac will be a multibillion company within a few years.
https://www.youtube.com/watch?v=ZJsozu5eIHs
Another one worth listening too. Slightly longer this time but really worth it!
https://www.youtube.com/watch?v=p9LU7aLdc-k
For all you doubters, have a listen to this!
https://www.youtube.com/watch?v=HydF9UhKXN8
For anyone interested who didn't attend the MI show.
Yes sure M'Lord. We all hope the board can pull off another Aphria in the near term. We may see it in Emmac as we know they are planning a float. Leap must be worth a bob or two now. Let's not forget they were nearly bought out two years ago which would have netted us $6 m, and that was before they started doing deals with global giants such as IMG. Our stake in Leap alone now must be worth our current market cap. We'll see!
I don't think anyone is suggesting that we are going to be stuck at these levels indefinitely as news could come out any time for any of the investments, but it's just that we need to be realistic and appreciate that this is a medium to long term investment. The investments we hold all have multi-bag potential, but because they nearly all start as private small companies they can take in some cases years before we see that multi-bag growth. Amongst the bio/medical companies value inflexion points in the near term which we know of are: Intensity phase1/2 trials completion next year, Juvenescence IPO next year, Emmac IPO soon. These three alone will be transformational to the FFWD share price. The other companies we can only speculate as to whether an IPO/sale will occur within the next few months, but we do know that companies like Factom, Leap, Vemo, Yooya are all growing at extraordinary rates, so when their time comes we will know about it! Patience is required in the meantime.
Hi O'Donnell, Emmac will be involved with the sale and distribution of medicinal cannabis across many countries. Green Monkey that you refer to is a CBD based product containing no psychoactive ingredients and hence perfectly legal and currently sold along with a myriad of other CBD containing food and drink based products.
This is not what Emmac is about though. Emmac is focused on medicinal cannabis which is only available upon prescription in this country, but which represents a market which is growing exponentially worldwide as the medicinal benefits of cannabis become ever more apparent.
Nice positive interview with Jim M. I particularly like the fact that he said Juvenescence would most probably list on the NYSE or Nasdaq early next year. Also Lygenesis trials to start next year. If early results are positive this should give a huge boost to the Juv share price momentum.
I'm not sure how much news we can expect this year as nothing seems to be imminent, but next year should be transformational. Intensity phase 1/2 trials concluding with buyout most probably shortly afterwards. Emmac to list also this or next year.
Fantastic topping up price currently!
https://www.new-casinos.uk/developers/leap-gaming/
Just come across this article. I'm not sure when it was written but it's an interesting read and a glowing endorsement of Leap.
Malachi, FDA approval will initially be for metastatic breast cancer and other applications will need to be made in other cancer areas. The significance of this first approval wil be hugely significant for Angle however and will really put Angle on the map as the first ever company to achieve FDA clearance for the harvesting of CTCs from patient blood for analysis. The Parsortix system is highly sensitive and can retrieve CTCs even in the early stages of cancer.
Just finished listening to the interview. Can't recommend it enough. It 's a truly inspiring interview which shows the enormous passion Lew has in trying to defeat cancer. It's a personal mission for him, and having started the company in such a humble way, in his basement, just adds to the very personal dimension of it all.
Mat I think you in particular will enjoy it!
have tweeted links to two very interesting Lew Bender interviews.
Another Lew Bender interview! Can view it via twitter also.
https://soundcloud.com/forbesbooks_radio/lewis-h-bender-founder-ceo
https://endpts.com/ai-drug-discovery-success-inspires-a-machine-learning-startup-at-the-mayo-clinic/
Referencing back to the article in the Telegraph it is quite possible that Insilico Medicine have a hand in this development bearing in mind The Mayo Clinic's involvement in AI.